GLP-1 Medication Costs in 2026: Insurance Coverage, Savings Programs, and What Patients Actually Pay

Medically reviewed by the UTCardiothoracicSurgery.com editorial team | Published April 2026

Disclaimer: This article is for educational purposes only. Pricing and insurance coverage are subject to change. Verify current costs with your pharmacy, insurance provider, and healthcare team. We have no financial relationship with any medication manufacturer or telehealth provider mentioned.

GLP-1 Medication Costs in 2026: What Patients Actually Pay

Let's be direct: cost is the single biggest barrier to GLP-1 medication access for most patients. The clinical evidence for these medications is remarkable — but none of that matters if you can't afford to fill the prescription. Understanding the actual cost landscape, including brand pricing, insurance realities, manufacturer programs, and alternative access routes, is essential for making informed decisions.

This guide covers what things actually cost right now, not list prices from pharmaceutical company press releases. For the clinical overview of GLP-1 medications, see our complete GLP-1 guide.

Brand-Name Pricing: The Sticker Shock

Without insurance coverage or savings programs, here's what brand-name GLP-1 medications cost at retail pharmacies in 2026:

Ozempic® (semaglutide injection, for diabetes): approximately $900-1,000 per month.

Wegovy® (semaglutide injection, for weight loss): approximately $1,300-1,400 per month.

Wegovy® oral tablet (semaglutide pill, for weight loss): approximately $149 per month through select programs (introductory pricing for certain doses).

Rybelsus® (semaglutide oral, for diabetes): approximately $900-1,000 per month.

Mounjaro® (tirzepatide injection, for diabetes): approximately $1,000-1,100 per month.

Zepbound® (tirzepatide injection, for weight loss): approximately $1,000-1,100 per month.

Despite containing the same molecule, Wegovy injectable costs more than Ozempic because it's marketed for weight loss — a condition with higher demand and different insurance dynamics — and because the maximum dose (2.4 mg) is higher than Ozempic's (2 mg).

The Wegovy oral tablet launch at approximately $149 per month represents a significant pricing shift — it's the first branded GLP-1 option accessible to many cash-pay patients at a price point approaching compounded alternatives.

Insurance Coverage: The Real-World Picture

For diabetes indications (Ozempic, Mounjaro, Rybelsus): Most commercial insurance plans and Medicare Part D cover these medications with varying co-pays, typically $25-150 per month depending on your plan's formulary tier and whether you've met your deductible. Prior authorization is often required but generally approved with documented diabetes diagnosis and blood sugar levels.

For weight loss indications (Wegovy, Zepbound): Coverage is substantially more variable. As of 2026, Medicare still generally excludes weight loss medications from coverage (though legislation to change this is actively being considered). Many employer-sponsored plans exclude or limit weight loss medication coverage. Medicaid coverage varies by state.

Among commercial plans that do cover weight loss medications, additional hurdles often include prior authorization with documented medical necessity, evidence of previous weight loss attempts (typically 3-6 months of supervised diet and exercise), step therapy requirements (trying cheaper options first), BMI documentation above plan-specific thresholds, and annual coverage limits.

The landscape is shifting in patients' favor. The SELECT trial's cardiovascular evidence has strengthened the medical necessity argument, and several states have enacted or proposed legislation requiring obesity medication coverage. But progress is uneven, and many patients still face significant out-of-pocket costs.

Manufacturer Savings Programs

Novo Nordisk (Ozempic, Wegovy, Rybelsus): Offers savings cards that can reduce co-pays for commercially insured patients. Eligible patients with commercial insurance may pay as little as $25 per month for up to a specified number of fills. The Novo Nordisk Patient Assistance Program (PAP) provides free medication for qualifying uninsured patients with household incomes below specified thresholds.

Eli Lilly (Mounjaro, Zepbound): Offers the Lilly Insulin Value Program and savings cards for commercially insured patients. The Zepbound Savings Card can reduce costs to as low as $25 per month for eligible patients. Eli Lilly's patient assistance program similarly provides medication for qualifying uninsured or underinsured patients.

Important limitations: Manufacturer savings cards typically don't work with Medicare, Medicaid, or other government-funded insurance. They often have annual or per-fill caps. They may require commercial insurance that covers the medication (even partially) as a prerequisite. And they can be discontinued or modified by the manufacturer at any time.

Compounded GLP-1 Medications: The Lower-Cost Alternative

Compounded semaglutide from telehealth providers typically costs $179-299 per month. Compounded tirzepatide runs approximately $299-399 per month. These prices usually include the medical consultation, the medication, and shipping — making them all-inclusive compared to brand-name options where you might pay separately for the office visit, prescription, and pharmacy fill.

The tradeoff is that compounded medications are not FDA-approved, haven't been tested in clinical trials, and quality can vary between providers. We cover this in comprehensive detail in our compounded vs. brand-name guide.

HSA and FSA Eligibility

Both brand-name and compounded GLP-1 medications are generally eligible for Health Savings Account (HSA) and Flexible Spending Account (FSA) reimbursement because they're prescribed medications for a medical condition. This effectively allows you to pay with pre-tax dollars, providing a 20-35% discount depending on your tax bracket. Check with your HSA/FSA administrator for specific eligibility rules.

Strategies to Reduce Your Out-of-Pocket Cost

Step 1: Check your insurance formulary. Before your appointment, call your insurance company and ask specifically whether Wegovy, Zepbound, Ozempic, and Mounjaro are covered under your plan, what tier they're on, and what prior authorization requirements exist.

Step 2: Ask your doctor about indication coding. If you have both obesity and a qualifying comorbidity (like diabetes, hypertension, or cardiovascular disease), your doctor may have flexibility in how the prescription is documented that affects coverage.

Step 3: Apply for manufacturer savings programs. Even before filling your first prescription, check eligibility for the Novo Nordisk or Eli Lilly savings programs through their websites or your prescriber's office.

Step 4: Consider the oral Wegovy option. At approximately $149 per month through qualifying programs, the Wegovy pill is the most affordable branded GLP-1 option for many cash-pay patients. See our oral GLP-1 guide for clinical details.

Step 5: Evaluate compounded options carefully. If brand-name medications are unaffordable even with savings programs, compounded semaglutide or tirzepatide through a reputable provider is a viable alternative for many patients. See our compounded guide for what to look for.

Step 6: Use HSA/FSA funds. If you have access to a health savings or flexible spending account, use pre-tax dollars to reduce the effective cost.

Step 7: If denied, appeal. Insurance denials for GLP-1 medications can often be overturned on appeal, particularly when your doctor provides documentation of medical necessity, failed prior weight loss attempts, and relevant comorbidities.

Frequently Asked Questions

What's the cheapest way to get semaglutide?

As of early 2026, the oral Wegovy tablet at approximately $149 per month (for qualifying patients) is the most affordable branded option. Compounded semaglutide from telehealth providers runs $179-299 per month. With commercial insurance and manufacturer savings cards, some patients pay as low as $25 per month for brand-name injectable versions.

Does Medicare cover GLP-1 medications?

Medicare Part D generally covers Ozempic and Mounjaro for diabetes management. Medicare has historically excluded weight loss medications from coverage, though legislation to change this policy is actively being considered. Check with your Part D plan for current coverage details.

Is compounded semaglutide worth the cost savings?

That depends on your risk tolerance and financial situation. The savings are significant ($179-299 vs. $900-1,400 per month), but you're accepting a product that hasn't undergone FDA review for safety and effectiveness. Our compounded vs. brand-name article helps you evaluate this tradeoff.

For the complete overview of GLP-1 medications and eligibility, return to our complete GLP-1 guide and who qualifies guide.

Pricing information reflects conditions as of early 2026 and is subject to change. Last reviewed: April 2026.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before starting any new supplement or health program, especially if you have existing medical conditions or take prescription medications.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any supplement, medication, or treatment program. Individual results may vary.